How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    1 Purpose of this document

    NICE's early value assessment guidance on digital front door technologies to gather information for assessments for NHS Talking Therapies for anxiety and depression recommends that more evidence on Limbic Access and Wysa Digital Referral Assistant is generated while they are being used in the NHS.

    This plan outlines the evidence gaps and what data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol but suggests an approach to generating the information needed to address the evidence gaps. For assessing comparative treatment effects, well-conducted randomised controlled trials are the preferred source of evidence.

    The companies are responsible for ensuring that data collection and analysis takes place.

    NICE will withdraw the guidance if the companies do not meet the conditions in section 4 on monitoring.

    After the end of the evidence generation period (3 years), the companies should submit the evidence to NICE in a form that can be used for decision making. NICE will review all the evidence and assess whether the technologies can be routinely adopted in the NHS.